Public Market Listing
Live quotes, historical charts, and market capitalization for Orion Corporation are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
entacapone(Comtess) | Approved | COMTSmall molecule | Parkinson's Disease |
Levosimendan(Simdax) | Phase 3 | Cardiac troponin C (calcium sensitizer)Small molecule | Heart FailurePulmonary Hypertension due to Left Heart Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $1.4B | $163M | $263M | — | report ↗ |
Orion Corporation reported revenue of $1,395.54M, up 14.7% YoY, R&D spend of $163.37M, up 27.0% YoY, and cash and equivalents of $263.05M for Q3 2025.
Figures only: this period's report disclosed no narrative text
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $842M | $98M | $215M | — | report ↗ |
| 2025-Q1 | $373M | $43M | $281M | — | report ↗ |
| 2024-Q3 | $1.2B | $129M | $212M | — | report ↗ |
| 2024-H1 | $689M | $87M | $163M | — | report ↗ |
| 2024-Q1 | $335M | $40M | $203M | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $2.1B | $239M | $189M | — | report ↗ |